Glucagon receptor modulators
AssigneePfizer Inc.
InventorsGary Erik Aspnes, Mary Theresa Didiuk, Kevin James Filipski, Angel Guzman-Perez, Esther Cheng Yin Lee, Jeffrey Allen Pfefferkorn, Benjamin Dawson Stevens, Meihua Mike Tu
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
Claims18
A compound of Formula I
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is a 5 membered heteroaryl group attached through either a carbon or nitrogen atom and which is optionally fused to a (C4-C7)cycloalkyl, phenyl or 6 membered heteroaryl;
- wherein the optionally fused 5 membered heteroaryl is optionally substituted with one to four substituents each independently selected from halo, —S(O)2—(C1-C3)alkyl, —S—(C1-C3)alkyl, hydroxy, —C(O)NRaRb, (C3-C5)cycloalkyl, cyano, phenyl which is optionally substituted with one to three halo, cyano, (C1-C3)alkyl or (C1-C3)alkoxy, 6 membered heteroaryl which is optionally substituted with one to three halo, cyano, (C1-C3)alkyl or (C1-C3)alkoxy, (C1-C6)alkyl optionally substituted with one to three fluoro, or (C1-C6)alkoxy optionally substituted with one to three fluoro;
- Ra and Rb are each independently H or (C1-C3)alkyl;
- R2 is H or methyl;
- R3 is tetrazolyl, —CH2-tetrazolyl, —(CH2)2SO3H or —(CH2)2CO2H, —CH2CHFCO2H or —CH2CHOHCO2H;
- A1, A2, A3 and A4 are each independently CR4 or N, with the proviso that no more than two of A1, A2, A3 and A4 are N;
- R4 at each occurrence is independently H, halo, cyano, (C1-C3)alkyl optionally substituted with one to three fluoro, or (C1-C3)alkoxy optionally substituted with one to three fluoro;
- L is —X—CH(R5)— or —CH(R5)—X—;
- X is CH2, O or NH;
- R5 is (C1-C6)alkyl which is optionally substituted with one to three fluoro, hydroxy or methoxy;
- (C3-C7)cycloalkyl which is optionally substituted with one to two (C1-C3)alkyl which are optionally substituted with one to three fluoro and wherein one to two carbons of the (C3-C7)cycloalkyl can be replaced with a NH, N(C1-C3)alkyl. O or S;
- or (C3-C7)cycloalkyl-(C1-C6)alkyl wherein the (C3-C7)cycloalkyl group of said (C3-C7)cycloakyl-(C1-C6)alkyl is optionally substituted with one to two (C1-C3)alkyl which are optionally substituted with one to three fluoro;
- B1, B2, B3 and B4 are each independently CR6 or N, with the proviso that no more than two of B1, B2, B3 and B4 are N;
- and
- R6 at each occurrence is independently H, halo, (C1-C3)alkyl optionally substituted with one to three fluoro, or (C1-C3)alkoxy optionally substituted with one to three fluoro.
3-(4-((3,3-dimethylcyclobutyl)(2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-5-yloxy)methyl)benzamido)propanoic acid, Isomer 1, or a pharmaceutically acceptable salt thereof.
3-(4-(1-(6-(4-tert-butyl-1H-pyrazol-1-yl)pyridin-3-ylamino)butyl)benzamido)propanoic acid, Isomer 2, or a pharmaceutically acceptable salt thereof.
3-(4-(cyclopentyl(6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyridine-3-ylamino)methyl)benzamido)propanoic acid, Isomer 1, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.